Common Nervous System Side Effects During Lurbinectedin Treatment
Lurbinectedin ( Zepzelca), approved for small cell lung cancer, causes nervous system effects that can persist or worsen with prolonged use beyond initial cycles. Fatigue affects over 50% of patients and often accumulates over time, linked to cumulative neurotoxicity [1]. Peripheral neuropathy, including paresthesia (tingling), dysesthesia (abnormal sensations), and hypoesthesia (reduced feeling), occurs in 20-30% of patients, with grade 3-4 severity rising in extended treatment due to axonal damage [2][3].
How Prolonged Use Increases Neuropathy Risk
In clinical trials like the phase 2 basket trial and confirmatory studies, neuropathy incidence doubled after 6+ cycles compared to early treatment. Symptoms stem from lurbinectedin's interference with DNA repair in sensory neurons, leading to progressive distal symmetric polyneuropathy. Median onset is cycle 4-6, with 10-15% of long-term users (12+ cycles) requiring dose reductions or discontinuation [2][4].
Severe or Long-Lasting Nervous System Reactions
Rare but serious effects include encephalopathy (confusion, altered mental status) in <2% of prolonged users, potentially irreversible, and seizures tied to hyponatremia from concurrent nausea. Headache and dizziness affect 15-20%, intensifying with duration and often overlapping with fatigue [1][3]. Post-treatment, 5-10% report persistent neuropathy lasting months.
What Patients Report in Prolonged Therapy
Real-world data from expanded access programs show chronic users experiencing insomnia (25%), anxiety/depression (15%), and gait instability from neuropathy, prompting monitoring via NCI-CTCAE grading every 2 cycles [4][5].
Management and Monitoring for Long-Term Use
Guidelines recommend baseline nerve conduction studies and monthly assessments. Dose adjustments (reduce by 25% for grade 2 neuropathy) or gabapentin/pregabalin help 60-70% of cases. Discontinue if grade 4 persists [1][3].
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com
[2]: Trigo et al., Lancet Oncology (2019), phase 2 trial data
[3]: FDA Label for Lurbinectedin, https://www.accessdata.fda.gov
[4]: Paz-Ares et al., J Clin Oncol (2021), long-term follow-up
[5]: ESMO Guidelines for SCLC, 2023